Search
Fondaparinux
go.drugbank.com/drugs/DB00569ApprovedInvestigationalThe monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII).
Products: ARIXTRA 12.5MG/ML SOLUTION FOR INJECTION, ARIXTRA 2.5MG/0.5ML SOLUTION FOR INJECTIONTechnetium Tc-99m sulfur colloid
go.drugbank.com/drugs/DB09397Approveda radiopharmaceutical diagnostic agent used in the evaluation of various conditions including lymph node metastases in breast cancer, detection of shunt patency, imaging of reticuloendothelial cells for
Products: Kit for the Preparation of Technetium Tc 99m Sulfur Colloid, Kit for the Prepartion of Technetium Tc99m Sulfur ColloidEpoprostenol
go.drugbank.com/drugs/DB01240ApprovedInvestigationalA prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary...
Products: VELETRI POWDER FOR SOLUTION FOR INFUSION 0.5MG/VIAL, VELETRI POWDER FOR SOLUTION FOR INFUSION 1.5MG/VIALPegfilgrastim
go.drugbank.com/drugs/DB00019ApprovedInvestigational[A187601] The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer … [L9974] NIOPEG (pegfilgrastim), a biosimilar of NEULASTA®, was approved by Health Canada in April 2024 for the prevention of febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive
Products: Pelgraz 6 mg solution for injection in a pre-filled syringe, Pelgraz Solution for Injection in pre-filled syringe 6mg/0.6mLEnfortumab vedotin
go.drugbank.com/drugs/DB13007ApprovedInvestigationalThe clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics [A188868] and it was first approved for use in the United States in December
Products: Padcev 30mg Powder for Concentrate for Solution for Infusion, Padcev 20mg Powder for Concentrate for Solution for InfusionExenatide
go.drugbank.com/drugs/DB01276ApprovedInvestigationalIt activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control[L42690].
Products: BYDUREON 2 mg powder and solvent for prolonged-release suspension for injection, BYDUREON POWDER AND SOLVENT FOR PROLONGED-RELEASE SUSPENSION FOR INJECTION IN PRE-FILLED PEN 2MGHydroxyethyl Starch
go.drugbank.com/drugs/DB09106ApprovedInvestigationalHydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume.
Mixtures: VOLULYTE 6% SOLUTION FOR INFUSION, VOLUVEN SOLUTION FOR INFUSION 6%Products: Volulyte 6% Solution for InfusionPaliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalPaliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. … It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor AntagonistsProducts: INVEGA Sustenna Prolonged Release Suspension for IM Injection 25mg/0.25 ml, INVEGA Sustenna Prolonged Release Suspension for IM Injection 50mg/0.5 mlAlemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigationalThe dose of alemtuzumab used for B-CLL is much higher than that for MS, and also at more frequent dosing.[L43397, L30335] … [L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).
Products: LEMTRADA Concentrate for Solution for Infusion 12 mg, LEMTRADA CONCENTRATE FOR SOLUTION FOR INFUSION 12 MG/ 1.2 MLEvolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is a monoclonal antibody designed for the treatment of hyperlipidemia by Amgen. … It is approved for both homozygous and heterozygous familial cholesterolemia as an adjunct to other first-line therapies.
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaProducts: REPATHA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 140MG/ML, Repatha Solution for Injection in Pre-filled Syringe 140mg/mL (evolocumab)